Quit-Smoking Drug Chantix Linked to Heart Risk
The popular quit-smoking drug Chantix poses a high risk of cardiovascular conditions, reveals a new study reported in the Canadian Medical Association Journal. Chantix (varenicline) can increase the chances of hospitalization due to arrhythmia or heart attack by 72%, reveals this study.
The lead investigator of the study says Chantix is a harmful prescription drug that has many side effects which have been reported previously to the FDA. The side effects include deterioration of diabetes condition, depression, violence, suicide, visual disturbances and loss of consciousness. To this list, the researchers have now added serious cardiovascular risks.
But Pfizer, the maker of Chantix has denied these allegations. There are more than a thousand complaints filed against Chantix’s side effects in US courts.
Chantix is used by about seven million people in the US and is sold in about 90 countries. In 2007, European health authorities had issued warnings about the side effects of Chantix including the risks of suicidal thoughts and depression. In France, Chantix is sold as Champix.